Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Spero Therapeutics (SPRO – Research Report) and Coherus Biosciences (CHRS – Research Report).
Spero Therapeutics (SPRO)
TD Cowen analyst Ritu Baral maintained a Hold rating on Spero Therapeutics yesterday. The company’s shares closed last Wednesday at $1.62.
According to TipRanks.com, Baral is a 4-star analyst with an average return of
Currently, the analyst consensus on Spero Therapeutics is a Moderate Buy with an average price target of $7.00.
See the top stocks recommended by analysts >>
Coherus Biosciences (CHRS)
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Coherus Biosciences on May 14 and set a price target of $7.00. The company’s shares closed last Wednesday at $2.18.
According to TipRanks.com, Devarakonda is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $9.20 average price target, which is a 340.2% upside from current levels. In a report issued on May 10, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SPRO:
- Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
- Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics files $300M mixed securities shelf
